A lawyer for Pennsylvania urged seven justices of the Pa. Commonwealth Court yesterday to allow the state’s case against Johnson & Johnson’s subsidiary Janssen to proceed, saying that a judge had “wrongfully taken the case away from the jury” in 2010. Among the evidence presented was a 1999 letter from the FDA to Janssen stating “The materials and promotional messages Janssen has disseminated contain false and/or misleading information about the safety and effectiveness of Risperdal.” One month ago, a judge awarded $1.1 billion in damages to Arkansas for a similar case, argued by the same lawyers.
State Argues $150 Mil. Risperdal Suit Should Have Gone to Jury
Pennsylvania Court to Hear Appeal of Dismissed Risperdal Lawsuit
J&J Fined $1.1 Billion for Hidden Risks of Risperdal
J&J Tries, Fails to Squeeze Whistle Blower in Texas Risperdal Case
Justice Department Raises J&J Settlement to $1.8 Billion
J&J Settles Texas Medicaid Lawsuit for $158 Million
J & J to Pay More Than $1 Billion For Wrongful Marketing of Risperdal
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.